Drugs / Lactobacillus and Bifidobacterium
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT06772090 Comparator | Dec 2026 → Dec 2027 expected | cancer, chemotherapy-induced toxicity | Masonic Cancer Center, University of Minnesota | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus and Bifidobacterium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06772090 ↗ |
| Route | Oral | “Lactobacillus and Bifidobacterium oral capsule, to be taken daily for 12 weeks” NCT06772090 ↗ |